Issue Date : March 16, 2013    Archives  
In this issue
Round-up
Fundamental - Volatile markets end the week lower...
Technical - Volatility at its best...

Sectoral outlook
Recommend mix of consumers and rate-sensitives...

Market outlook
Fundamental - Maintain bullish stance...
Technical - Market to remain choppy RBI to provide direction...

Calls you can execute
EdelStar - Buy Ranbaxy Laboratories Ltd.
CMP: Rs. 439 Target Price: Rs. 500

Fundamental

 

  • Despite some positves from the economic front, Indian markets ended lower in a largely volatile week.

  • The Index of Industrial prodcution for January rose for the fisrt time in 3-months coming in at 2.4% as agaisnt expectations of 1.3% ,with the manufacturing and electricity sectors contributing to the expansion while mining de-grew for the same period.

  • On the Inflation front, the CPI for Feburary came in at 10.91% as agaisnt 10.79% in the preceeding month on account of higher food prices.The WPI also inched up to 6.84% in February as against expectations of 6.67%, majorly attributed to the Fuel group price rise.A major positive was core inflation which came in at 3.8% as agaisnt expectations of 4.2%.

  • Most global markets traded in the green throughout the week, with the Dow registering its 10th successive session of gains and the Nikkei nearing a 4 ½-year high. European markets are within touching distance of multi-year highs as a result of investor optimism over the 2-day EU conference held at Brussels, which will address matters like high unemployment and the need to ease austerity measures to revive economic growth.

This Week’s Market Round Up: Volatile markets end the week lower...

  • Indian stock markets ended a highly volatility week in the red, with benchmark indices like the Sensex and Nifty ending with losses of 1% on a week on week basis.

  • The broader markets also remained under pressure with the BSE Small-Cap index was down 2.4% during the week and the BSE Mid-Cap index down 1.6%.

  • Auto, Banking and Consumer Durables were the major sectoral losers while the FMCG and Pharma Sectors were the notworthy gainers.

  • Ranbaxy, Siemens, Asian Paints, HUL and Tata Power were the main gainers in the NSE during the week.

  • Bajaj Auto, ICICI Bank, Hindalco, GAIL and Axis Bank were the biggest losers in the two main indices.

Index Value Change in Points % Change WoW
Sensex 19,427.56 -142.8 -1.3
Nifty 5,872.60 -36.25 -1.2
Mid-Cap 6,386.13 -101.02 -1.6
Small-Cap 6,231.76 -154.25 -2.4
Bank Nifty 11,816.55 -380.7 -3.1
  • FIIs invested INR 4,759 crore into Indian stocks between March 07 and March 14.

  • The Rupee ended the week at 54.0250 per US Dollar as against the previous week’s close of 54.2913 to the dollar. The weekly high and low stood at 54.4125 and 54.0250, respectively.

Market Outlook: Maintain bullish stance...

  • At the current level of 19,427.56, the Sensex trades at a PE of 15.5x FY13 earnings and 13.8x FY14E earnings estimate. At 15.5x, the Sensex trades near its historical average valuation of 15.0-16.0x one-year forward earnings.

  • The Indian government has moved on a number of important policy reforms in the form of FDI in retail, aviation, insurance & pension besides unleashing other measures like SEB debt restructuring and diesel price deregulation. The Union Budget has also been quite a balanced and credible one with more emphasis on fiscal correction.

  • So, the Indian markets will continue to advance over the next 12-18 months, as the Government’s policy measures start to bear fruit gradually. FIIs are likely to remain positive towards the Indian equities this year also, as the RBI is set to maintain its accommodative monetary policy stance.

  • We see the main Indian indices moving higher towards new all-time highs in the medium-term to long-term period.

Sectoral Outlook: Recommend mix of consumers and rate-sensitives...

  • The RBI in its January policy meeting cut both the repo rate and the CRR by 25 bps each, to support economic recovery, as it acknowledged that inflation is moderating at the wholesale level due to reduced demand. Although the central bank will be encouraged by the Finance Minister’s efforts to curtail the fiscal deficit over the next 2-3 years, it might be constrained if the current account deficit (CAD) and consumer inflation remain elevated.

  • We advice investors to play quality interest rate-sensitive shares like Banks and Capital Goods (ICICI Bank, J&K Bank, Bajaj Finance and L&T).

  • At the same time, in consumption we recommend buying into Astral Poly, Maruti, Coromandel Fertilizers and Amara Raja Batteries.

  • Other stocks we like include Mid-caps like Gateway Distriparks and Supreme Industries.

Outlook:

  • The Indian market has witnessed some volatility of late, with the main indices falling immediately in the wake of the Union Budget before staging a smart rebound this week. The outlook has improved over the course of this week, with Indian shares joining the global ‘risk-on’ rally. Next week is an important one, as the Government will release data on IIP, WPI inflation, CPI inflation and Foreign Trade. Also, the markets will brace for the March 19 RBI policy meeting to see if the central bank persists with its accommodative monetary stance.

EdelStar - Buy Ranbaxy Laboratories Ltd.
CMP: Rs. 439 Target Price: Rs. 500

Time Horizon – 3 months

  • Ranbaxy Laboratories (RANLAB) incorporated in 1961, is India’s largest pharma company with presence in domestic, emerging, and regulated markets. The company has strong presence in the domestic market and ranks No. 2 as per IMS. Over the years it has build a well diversified model with presence in various international markets (including LATAM, Europe, Russia, Africa, Asia, US and Canada) which renders sustainable growth to overall business. In 2008, the second generation promoters sold their stake to Daiichi Sankyo, which now owns ~64% in the company.

  • Core growth to remain in double digits: The underlying growth in base sales was a robust 10% in CY12 (versus 2% reported), while overall growth was 15% (versus 9% reported). Management expects growth momentum to continue led by higher contribution from US on back of launches such as Absorica, Desvenlafaxine and Lipitor. We estimate 14% core sales CAGR over CY13-14E.

  • Lumpiness in fixed costs singed margin: The lumpiness of costs from remediation efforts at effected plants and Lipitor recall resulted in an unimpressive margin performance of 3% during Q4CY12 versus 10.7% core margin in 9mCY12. We believe this is an aberration and scale up in base business will result in margin recovery Q2CY13 onwards.

To read more click here >>

Technical

Round-up: Volatility at its best...

  • After opening the week on a flat note, some buying was witnessed and the Nifty made a high of 5971. However on higher levels selling pressure was witnessed and the Nifty shed all its gain and made a low of 5791. Finally the Nifty closed at 5872 with a loss of 1.18%.

  • Market breadth was mixed bag throughout the week.

  • Banking stocks were the major looser during the week.

Nifty Outlook: Market to remain choppy RBI to provide direction...

  • On the daily chart, the Nifty has already retraced 61.80% of the recent rally from 5663 to 5971. Besides this, oscillators are trading in a neutral range. Thus, going forward we may see lot of volatility in the market and Nifty will be trading in a broad range of 5850-6000 levels. However, a breach of this range either side will lead to a sharp upside or downside movement in the markets.

Disclaimer:

This document has been prepared by Edelweiss Financial Advisors Limited (Edelweiss). Edelweiss, its holding company and associate companies are a full service, integrated investment banking, portfolio management and brokerage group. Our research analysts and sales persons provide important input into our investment banking activities. This document does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Specifically, this document does not constitute an offer to or solicitation from any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. The information contained herein is from publicly available data or other sources believed to be reliable, but we do not represent that it is accurate or complete and it should not be relied on as such. Edelweiss or any of its affiliates/ group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. This document is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult his own advisors to determine the merits and risks of such investment. The investment discussed or views expressed may not be suitable for all investors. We and our affiliates, group companies, officers, directors, and employees may: (a) from time to time, have long or short positions in, and buy or sell the securities and/or derivatives thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and/or derivatives and earn brokerage or other compensation or act as advisor or lender/borrower to such company (ies) or have other potential conflict of interest with respect to any recommendation and related information and opinions. This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Edelweiss and affiliates/ group companies to any registration or licensing requirements within such jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law, and persons in whose possession this document comes, should inform themselves about and observe, any such restrictions. The information given in this document is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. Edelweiss reserves the right to make modifications and alterations to this statement as may be required from time to time. However, Edelweiss is under no obligation to update or keep the information current. Nevertheless, Edelweiss is committed to providing independent and transparent recommendation to its client and would be happy to provide any information in response to specific client queries. Neither Edelweiss nor any of its affiliates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. Past performance is not necessarily a guide to future performance. The disclosures of interest statements incorporated in this document are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. Edelweiss Financial Advisors Limited generally prohibits its analysts, persons reporting to analysts and their family members from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report. Please note that Mutual Fund Investments are subject to market risks, read the offer document carefully of the respective schemes before investing for full understanding and detail. Kindly read the Risk Disclosure Documents carefully before investing in Equity Shares, Derivatives, Commodities or other instruments. The information provided in these reports remains, unless otherwise stated, the copyright of Edelweiss. All layout, design, original artwork, concepts and other Intellectual Properties, remains the property and copyright Edelweiss and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the copyright holders. The contents of this Research Report are intellectual property rights of Edelweiss Financial Advisors Limited. All rights reserved.